$BCAX insider trading
Over the last 12 months, Bicara Therapeutics insiders reported 1 buy totaling $4.8M and 31 sales totaling $9.4M across SEC Form 4 filings. 97% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $4.8M 1 event
- Sold · 12m
- $9.4M 31 events
- Events · 12m
- 32 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 97% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO · O·D | ▼ Sale | 17,500 | $22.9 | $401K | -8.8% | plan · 2 tranches |
| Aug 10, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 12,500 | $27.97 | $350K | -8.8% | plan |
| Aug 10, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 10,000 | $27.98 | $280K | -2.7% | plan |
| Aug 10, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 18,750 | $27.98 | $525K | -9.4% | plan |
| Jul 10, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 10,000 | $28.42 | $284K | -2.7% | plan · 2 tranches |
| Jul 9, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 28,750 | $28.98 | $833K | -13.7% | plan · 4 tranches |
| Jul 8, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 28,000 | $28.85 | $808K | -17.7% | plan · 3 tranches |
| May 21, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 9,200 | $20.42 | $188K | -6% | plan |
| Apr 27, 2026 | Raben DavidChief Medical Officer · O | ▼ Sale | 5,500 | $22.88 | $126K | -9% | plan |
| Apr 21, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 9,200 | $23 | $212K | -6% | plan |
| Apr 20, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 15,000 | $23.61 | $354K | -4% | plan |
| Apr 15, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 12,500 | $23.01 | $288K | -6% | plan · 2 tranches |
| Mar 25, 2026 | Raben DavidChief Medical Officer · O | ▼ Sale | 5,500 | $18.95 | $104K | -9% | plan |
| Mar 23, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 9,200 | $18.52 | $170K | -6% | plan |
| Mar 20, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 15,000 | $18.82 | $282K | -4.2% | plan · 3 tranches |
| Mar 16, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 12,500 | $19.66 | $246K | -5.9% | plan · 2 tranches |
| Mar 9, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 36,766 | $19.17 | $705K | -9.8% | plan |
| Mar 6, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 8,234 | $18.74 | $154K | -2.4% | plan · 3 tranches |
| Mar 4, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 16,518 | $18.22 | $301K | -10.2% | plan · 2 tranches |
| Mar 4, 2026 | Raben DavidChief Medical Officer · O | ▼ Sale | 16,500 | $18.52 | $306K | -23% | plan · 2 tranches |
| Mar 3, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 17,392 | $18.16 | $316K | -7.8% | plan · 2 tranches |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P.D·10% | ▲ Buy | 300,000 | $16 | $4.8M | +7% | indirect |
| Feb 25, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 3,631 | $18.04 | $66K | -1.7% | plan · 2 tranches |
| Jan 22, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 3,828 | $18.1 | $69K | -1.8% | plan |
| Jan 22, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 1,882 | $18.15 | $34K | -1.3% | plan |
| Jan 15, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 149 | $18.02 | $3K | -0.1% | plan |
| Dec 22, 2025 | Hyep IvanChief Financial Officer · O | ▼ Sale | 9,200 | $18.31 | $168K | -6% | plan |
| Dec 15, 2025 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 12,500 | $18.68 | $234K | -6.2% | plan · 2 tranches |
| Nov 25, 2025 | Raben DavidChief Medical Officer · O | ▼ Sale | 11,000 | $18.65 | $205K | -23.7% | plan · 3 tranches |
| Nov 24, 2025 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 41,163 | $18.86 | $776K | -11.7% | plan |
| Nov 24, 2025 | Hyep IvanChief Financial Officer · O | ▼ Sale | 18,400 | $18.54 | $341K | -11.2% | plan · 2 tranches |
| Nov 21, 2025 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 12,500 | $18.05 | $226K | -6.1% | plan · 2 tranches |
| Oct 16, 2025 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 24,103 | $18.83 | $454K | -7.2% | plan |
| Oct 15, 2025 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 12,500 | $18.16 | $227K | -5.9% | plan · 2 tranches |
| Oct 15, 2025 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 24,734 | $18.88 | $467K | -7.4% | plan · 2 tranches |
| Oct 9, 2025 | Raben DavidChief Medical Officer · O | ▼ Sale | 22,000 | $18.45 | $406K | -38.3% | plan |
| Oct 9, 2025 | Hyep IvanChief Financial Officer · O | ▼ Sale | 6,415 | $18.23 | $117K | -4.2% | plan |
| Oct 8, 2025 | Hyep IvanChief Financial Officer · O | ▼ Sale | 30,385 | $18.21 | $553K | -17.3% | plan · 3 tranches |
| Oct 7, 2025 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 50,500 | $18.06 | $912K | -19.9% | plan · 4 tranches |
| Sep 29, 2025 | Meisner LaraChief Legal Officer · O | ▼ Sale | 33,807 | $14.75 | $499K | -100% | plan |
| Sep 15, 2025 | Meisner LaraChief Legal Officer · O | ▼ Sale | 15,829 | $11.49 | $182K | -100% | plan |
Every $BCAX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Bicara Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BCAX feed.